At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 190 enrolled
Drug / intervention
Brimonidine 0.33% gel (Br) +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of Ivermectin 1% Topical Cream Associated With Brimonidine 0.33% Topical Gel in the Treatment of Moderate to Severe Rosacea
In Brief
A Phase 4 clinical trial evaluating Brimonidine 0.33% gel (Br), CD07805/47 (Br) placebo gel, and 2 other interventions for Rosacea. Completed, enrolled 190 participants across 13 sites in 2 countries.
Detailed Summary
The main objective of this study is to evaluate the efficacy of Ivermectin 1% cream (IVM) associated with Brimonidine 0.33% gel (Br) compared with the association of their respective vehicles in the treatment of moderate to severe rosacea.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRosacea
CountriesCanada, United States
Collaborators--
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedNov 2015
Enrollment StartDec 2015
Primary CompletionSep 2016
TodayJul 2026
First PostedNov 26, 2015
Enrollment StartDec 1, 2015
Primary CompletionSep 1, 2016
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 10.6 years ago
Interventions
Brimonidine 0.33% gel (Br)drug
CD07805/47 (Br) placebo gelother
Ivermectin 1% cream (IVM)drug
CD5024 (IVM) placebo creamother